JP2009513660A - 肺動脈性高血圧の治療用併用療法におけるファスジル - Google Patents

肺動脈性高血圧の治療用併用療法におけるファスジル Download PDF

Info

Publication number
JP2009513660A
JP2009513660A JP2008537949A JP2008537949A JP2009513660A JP 2009513660 A JP2009513660 A JP 2009513660A JP 2008537949 A JP2008537949 A JP 2008537949A JP 2008537949 A JP2008537949 A JP 2008537949A JP 2009513660 A JP2009513660 A JP 2009513660A
Authority
JP
Japan
Prior art keywords
fasudil
therapeutic combination
combination according
group
sarpogrelate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008537949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009513660A5 (enExample
Inventor
フオン，ベンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of JP2009513660A publication Critical patent/JP2009513660A/ja
Publication of JP2009513660A5 publication Critical patent/JP2009513660A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008537949A 2005-10-26 2006-10-25 肺動脈性高血圧の治療用併用療法におけるファスジル Pending JP2009513660A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73027305P 2005-10-26 2005-10-26
PCT/US2006/041830 WO2007050783A2 (en) 2005-10-26 2006-10-25 Fasudil in combination therapies for the treatment of pulmonary arterial hypertension

Publications (2)

Publication Number Publication Date
JP2009513660A true JP2009513660A (ja) 2009-04-02
JP2009513660A5 JP2009513660A5 (enExample) 2009-08-20

Family

ID=37814479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008537949A Pending JP2009513660A (ja) 2005-10-26 2006-10-25 肺動脈性高血圧の治療用併用療法におけるファスジル

Country Status (5)

Country Link
US (3) US7893050B2 (enExample)
EP (2) EP2111863B1 (enExample)
JP (1) JP2009513660A (enExample)
AT (1) ATE551059T1 (enExample)
WO (1) WO2007050783A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149012A1 (ja) * 2010-05-27 2011-12-01 参天製薬株式会社 イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の予防または治療方法、イソキノリンスルホニル誘導体またはその医薬的に許容される塩、ならびにその使用
JP2013501032A (ja) * 2009-08-07 2013-01-10 サイファーム ソシエテ ア レスポンサビリテ リミテ 嚢胞性線維症の治療のための組成物
JP2014505082A (ja) * 2011-02-07 2014-02-27 サイファーム ソシエテ ア レスポンサビリテ リミテ 嚢胞性線維症の処置のための新規組成物
WO2017170981A1 (ja) * 2016-04-01 2017-10-05 国立大学法人京都大学 Ｆｇｆｒ３病の予防または治療剤
JP2020513028A (ja) * 2017-04-11 2020-04-30 セバ・サンテ・アニマル 哺乳動物における心疾患の処置方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2580108T3 (es) * 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
US20070135499A1 (en) * 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010103040A1 (en) * 2009-03-10 2010-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US8871781B2 (en) 2011-11-30 2014-10-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject for a lymphatic malformation
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
KR102276424B1 (ko) 2014-10-06 2021-07-12 삼성전자주식회사 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
KR20160049435A (ko) 2014-10-27 2016-05-09 삼성전자주식회사 Atm 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
EP3112466A1 (en) 2015-07-01 2017-01-04 Samsung Electronics Co., Ltd. Composition for reducing cellular senescence level including activity inhibitor inhibiting dcun1d3 activity or expression inhibitor inhibiting expression of dcun1d3-encoding gene and use thereof
US12048761B2 (en) * 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2017086941A1 (en) 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals, Inc. métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US20190125756A1 (en) * 2017-11-01 2019-05-02 Cipla Limited Method of treating hypertension
WO2020047220A1 (en) * 2018-08-30 2020-03-05 The Trustees Of Indiana University Materials and methods for suppressing and/or treating cancer and/or cancer treatment induced cardiac toxicity
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11413289B2 (en) 2019-05-16 2022-08-16 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
JP2023550463A (ja) * 2020-11-23 2023-12-01 エアロベイト セラピューティクス， インコーポレイテッド イマチニブ処方物、その製造および使用
WO2022245708A1 (en) * 2021-05-19 2022-11-24 Woolsey Pharmaceuticals, Inc. Methods of treating depression and anxiety
MX2023013538A (es) * 2021-05-19 2023-11-27 Woolsey Pharmaceuticals Inc Metodos para tratar la depresion y la ansiedad.
CA3236338A1 (en) * 2021-11-12 2023-05-19 Woolsey Pharmaceuticals, Inc. Method of treating amyotrophic lateral sclerosis and dosing regimen for same
MX2024009983A (es) 2022-02-17 2024-08-26 Woolsey Pharmaceuticals Inc Formulaciones orales de fasudil que enmascaran el sabor.
MX2024010030A (es) 2022-02-17 2024-09-24 Woolsey Pharmaceuticals Inc Formulaciones orales de fasudil con resina de intercambio ionico.
CN121463952A (zh) * 2023-05-12 2026-02-03 得克萨斯A&M大学系统 用于微血管功能障碍及相关疾病的诊断和治疗的组合物和方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US56403A (en) * 1866-07-17 Improved machine for grinding cutlery
US2882271A (en) 1959-04-14 Xcixcxh
US110553A (en) * 1870-12-27 Improvement in preventing incrustation of steam-boilers
US377393A (en) * 1888-02-07 Dyeing or scouring machine
US326704A (en) * 1885-09-22 James h
US3746A (en) * 1844-09-17 Improvement in coating iron and copper with tin and other metals
US870767A (en) * 1907-02-11 1907-11-12 Robert J Emory & Company Spooling-machine.
BE578515A (enExample) 1958-05-07
US3047591A (en) * 1959-08-31 1962-07-31 British Drug Houses Ltd Preparation of 17alpha-acyloxy-6alpha-methyl-16-methylenepregn-4-ene-3,20-diones
DE1265758B (de) 1960-05-25 1968-04-11 Guidotti & C Spa Labor Verfahren zur Herstellung von o-(beta-Dialkylaminoaethoxy)-phenylketonen und deren Saeureadditionssalzen und quartaeren Salzen
DE1170417B (de) 1960-11-08 1964-05-21 Recip Ab Verfahren zur Herstellung eines Diphenyl-butylamins mit die Coronargefaesse erweiternder Wirkung
DE1154810B (de) 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
US3262977A (en) 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
BR6464291D0 (pt) 1963-11-26 1973-07-26 Merrell Inc Richardson Processo para preparar o novo composto quimico 1-1-di cloro-hexil-2-(2-piperidil)-etina
NL137318C (enExample) 1964-06-09
FR1406805A (fr) 1964-08-17 1965-07-23 Egyt Gyogyszervegyeszeti Gyar Procédé de préparation de nouveaux éthers basiques de cycloalkanols substitués
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US3562257A (en) 1967-10-28 1971-02-09 Tanabe Seiyaku Co Benzothiazepine derivatives
DE2117571C3 (de) 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3773939A (en) 1971-11-24 1973-11-20 Janssen Pharmaceutica Nv N-arallyl-n'-aralkyl piperazine pharmaceutical compositions
BE795735A (fr) 1972-03-06 1973-06-18 Cerm Cent Europ Rech Mauvernay Nouvelles ethylenediamines substituees a activite cardiovasculaire
US3985758A (en) 1973-02-20 1976-10-12 Yamanouchi Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives
US4338322A (en) 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
US4154839A (en) 1975-11-05 1979-05-15 Bayer Aktiengesellschaft 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine
US4466972A (en) 1977-06-20 1984-08-21 Sandoz Ltd. Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them
JPS55301A (en) 1978-02-14 1980-01-05 Yamanouchi Pharmaceut Co Ltd 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation
SE429652B (sv) 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
GB2111978B (en) 1981-10-19 1985-05-01 Maruko Pharmaceutical Co 1 4-dihydropyridine compounds
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
ATE50987T1 (de) 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
AU557175B2 (en) 1982-10-15 1986-12-11 Kyowa Hakko Kogyo Co. Ltd. 2,6-dimethyl-4-(3-nitro phenyl)-1,4-dihydro pyridine-3,5- dicarboxylic acid esters
US4451244A (en) 1982-11-30 1984-05-29 Borg-Warner Corporation Series vibration damper with non-symmetrical curve
US4567175A (en) 1983-06-03 1986-01-28 Tanabe Seiyaku Co., Ltd. 8-Chloro-1,5-benzothiazepine derivatives
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
JPS60222472A (ja) 1984-03-30 1985-11-07 Kanebo Ltd 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物
US4672068A (en) 1984-05-04 1987-06-09 Fujirebio Kabushiki Kaisha Antihypertensive 1,4-dihydropyridines having a conjugated ester
NZ212895A (en) 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
AU587057B2 (en) 1985-07-29 1989-08-03 Santen Pharmaceutical Co. Ltd. 1,4-dihydro-3-oxo-2-(substituted phenyl)-benzothiazine derivatives
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
CA1319144C (en) 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
DE3768658D1 (de) 1987-08-03 1991-04-18 Delagrange Lab 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
JPH06141894A (ja) 1992-11-11 1994-05-24 Asahi Chem Ind Co Ltd ミオシン軽鎖リン酸化酵素の活性測定法
DE69606721T2 (de) 1995-07-03 2000-06-21 Asahi Kasei Kogyo K.K., Osaka 1-(5-isochinolinsulfonyl)homopiperazin hydrochlorid
PT956865E (pt) * 1996-08-12 2007-07-30 Mitsubishi Pharma Corp Medicamentos compreendendo inibidores da rho cinase.
US6147109A (en) 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (en) 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
WO2000056403A1 (en) 1999-03-19 2000-09-28 The Brigham And Women's Hospital, Inc. UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
US6228843B1 (en) 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
AU2002349411A1 (en) 2001-11-30 2003-06-17 Asahi Kasei Pharma Corporation Remedies for primary pulmonary hypertension
FR2833840B1 (fr) 2001-12-21 2010-06-18 Rytek Methodes et compositions pour le traitement de pathologies respiratoires
KR101160780B1 (ko) 2002-08-29 2012-06-27 산텐 세이야꾸 가부시키가이샤 Ｒｈｏ 키나아제 억제제 및 프로스타글란딘류를 포함하는 녹내장 치료제
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
AT510757B1 (de) 2010-11-15 2014-01-15 Siemens Ag Oesterreich System zur fehlersicheren und redundanten übertragung von komplexen daten

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501032A (ja) * 2009-08-07 2013-01-10 サイファーム ソシエテ ア レスポンサビリテ リミテ 嚢胞性線維症の治療のための組成物
WO2011149012A1 (ja) * 2010-05-27 2011-12-01 参天製薬株式会社 イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の予防または治療方法、イソキノリンスルホニル誘導体またはその医薬的に許容される塩、ならびにその使用
JP2014505082A (ja) * 2011-02-07 2014-02-27 サイファーム ソシエテ ア レスポンサビリテ リミテ 嚢胞性線維症の処置のための新規組成物
WO2017170981A1 (ja) * 2016-04-01 2017-10-05 国立大学法人京都大学 Ｆｇｆｒ３病の予防または治療剤
JP2020513028A (ja) * 2017-04-11 2020-04-30 セバ・サンテ・アニマル 哺乳動物における心疾患の処置方法
JP7148545B2 (ja) 2017-04-11 2022-10-05 セバ・サンテ・アニマル 哺乳動物における心疾患の処置方法

Also Published As

Publication number Publication date
EP2111863B1 (en) 2012-03-28
WO2007050783A2 (en) 2007-05-03
US8476259B2 (en) 2013-07-02
EP2111863A1 (en) 2009-10-28
US20130005711A1 (en) 2013-01-03
US20070111983A1 (en) 2007-05-17
EP1951253A2 (en) 2008-08-06
US20110171139A1 (en) 2011-07-14
US7893050B2 (en) 2011-02-22
WO2007050783A3 (en) 2007-12-21
ATE551059T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
US8476259B2 (en) Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US20070197544A1 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
AU2020203936B2 (en) The use of isosteviol in the manufacture of medicament for treatment of cardiac fibrosis remodeling
AU2007220047B2 (en) Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
JP2018135383A (ja) 肺高血圧症のための治療
KR100750384B1 (ko) 흡입에 의하여 벤진덴 프로스타글란딘을 투여하는 방법
KR20240068077A (ko) 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
US10016397B2 (en) Selective AT2 receptor agonists for use in treatment of cachexia
Galiè et al. Emerging medical therapies for pulmonary arterial hypertension
EP2351569B1 (en) Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
Abshagen Organic nitrates
RU2345769C2 (ru) Комбинация вориконазола и противогрибкового ингибитора cyp2c19
JP2010514841A (ja) 肺疾患および心疾患の処置におけるシクレタニンおよびｐｋｃ阻害剤
US20250177384A1 (en) Chromanol compounds for treatment or prophylaxis of ageing-associated disorders
HK40115454A (en) Chromanol compounds for treatment or prophylaxis of ageing-associated disorders
MXPA06003273A (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
JP2005060359A (ja) 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用
JP2002338467A (ja) アデニル酸シクラーゼ５型阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090701

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20091208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120529